心脏骤停后血压目标与管理
本文综述心脏骤停后ICU患者的血压管理。指南推荐目标MAP高于65-70 mmHg,使用液体复苏和升压药。流行病学数据显示近50%患者出现需升压药的低血压。高MAP理论上可增加冠脉血流,但升压药可能增加心肌氧耗和心律失常;脑自动调节受损者可能需要更高MAP。4项研究(1000余例)比较高低MAP目标,组间MAP平均差值10-15 mmHg;贝叶斯Meta分析提示未来研究组间效应差超过5%的后验概率低于50%,高MAP目标伤害可能性也低。现有研究主要针对心脏原因骤停和可除颤初始心律患者,未来研究应纳入非心脏原因并扩大组间MAP差值。
要点
- 当前指南推荐心脏骤停后目标MAP高于65-70 mmHg,使用液体复苏和升压药。
- 流行病学数据显示近50%心脏骤停后患者出现需升压药的低血压。
- 高MAP理论上增加冠脉血流,但升压药可能增加心肌氧耗和心律失常风险。
- 4项研究(1000余例)比较高低MAP目标,组间MAP平均差值10-15 mmHg;贝叶斯Meta分析提示未来研究组间效应差超过5%的后验概率低于50%,高MAP目标伤害可能性也低。
- 现有研究主要纳入心脏原因骤停和可除颤初始心律患者,未来研究应纳入非心脏原因并扩大组间MAP差值。
适用人群与场景
- 心脏骤停后入住ICU治疗的患者;现有研究主要针对心脏原因骤停且多数为可除颤初始心律复苏的患者。
诊断标准与关键阈值
- 当前指南推荐目标平均动脉压(MAP)高于65-70 mmHg。
处置流程与药物剂量
- 使用液体复苏和升压药以达到目标MAP高于65-70 mmHg。
- 管理策略因场景(院前与院内阶段)而异。
红旗征与不能漏的情况
- 近50%心脏骤停后患者出现需升压药的低血压。
- 脑自动调节可能受损,需更高MAP以避免脑血流下降。
研究设计与关键结果
- 4项研究共纳入1000余例患者,比较较低与较高MAP目标,组间达到的MAP平均差值10-15 mmHg。
- 基于这些研究的贝叶斯Meta分析提示,未来研究组间治疗效应差超过5%的后验概率低于50%,高MAP目标伤害可能性也低。
证据类型、等级与局限
- 综述;现有4项研究主要聚焦心脏原因骤停和可除颤初始心律患者。
- 局限:现有研究主要针对心脏原因骤停且多数为可除颤初始心律,未来研究应纳入非心脏原因并扩大组间MAP差值。
对床旁实践的改变
- 当前指南推荐心脏骤停后目标MAP高于65-70 mmHg,使用液体复苏和升压药。
- 高MAP目标理论上增加冠脉血流,但升压药可能增加心肌氧耗和心律失常风险;脑自动调节受损者可能需要更高MAP。
- 现有证据提示更高MAP目标获益超过5%差值的可能性低,但伤害可能性也低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Blood pressure is one modifiable physiological target in patients treated in the intensive care unit after cardiac arrest. Current Guidelines recommend targeting a mean arterial pressure (MAP) of higher than 65-70 mmHg using fluid resuscitation and the use of vasopressors. Management strategies will vary based in the setting, i.e. the pre-hospital compared to the in-hospital phase. Epidemiological data suggest that some degree of hypotension requiring vasopressors occur in almost 50% of patients. A higher MAP could theoretically increase coronary blood flow but on the other hand the use of vasopressor may result in an increase in cardiac oxygen demand and arrhythmia. An adequate MAP is paramount for maintaining cerebral blood flow. In some cardiac arrest patients the cerebral autoregulation may be disturbed resulting in the need for higher MAP in order to avoid decreasing cerebral blood flow. Thus far, four studies including little more than 1000 patients have compared a lower and higher MAP target in cardiac arrest patients. The achieved mean difference of MAP between groups has varied from 10-15 mmHg. Based on these studies a Bayesian meta-analysis suggests that the posterior probability that a future study would find treatment effects higher than a 5% difference between groups to be less than 50%. On the other hand, this analysis also suggests, that the likelihood of harm with a higher MAP target is also low. Noteworthy is that all studies to date have focused mainly on patients with a cardiac cause of the arrest with the majority of patients being resuscitated from a shockable initial rhythm. Future studies should aim to include also non-cardiac causes and aim to target a wider separation in MAP between groups.
参考来源
- Skrifvars MB, Ameloot K, Åneman A, et al. Blood pressure targets and management during post-cardiac arrest care. Resuscitation. 2023. PMID: 37380065. doi:10.1016/j.resuscitation.2023.109886
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。